Suppr超能文献

英格兰农村社区心理健康团队抗精神病药物处方模式研究

Study on the prescribing patterns of antipsychotic medication in a rural England Community Mental Health Team.

作者信息

Seshadri Madhavan, Elsemary Ahmed, Thalitaya Madhusudan Deepak, Chikodzore Lawrence, Nagalingam Priya

机构信息

2gether NHS Trust Foundation Trust, Herefordshire Recovery Services, The Knoll, Ross-on-Wye, Herefordshire, HR9 5NA, UK,

出版信息

Psychiatr Danub. 2017 Sep;29(Suppl 3):524-529.

Abstract

INTRODUCTION

Providing comprehensive services for about 400 patients in the South Herefordshire area, the community mental health team manages cases of varying severity and complexity, ranging from Schizophrenia, to neuroses and disorders of adult personality. Antipsychotic medication remains a mainstay of treatment and management for patients under the team case load; hence a need exists for a detailed look into the prescription patterns of such medications.

AIM

The aim of this study was to look into the prescribing patterns of antipsychotics for a sample of 50 patients in the South Herefordshire community team during the year of 2016 (from Jan 2016 to Dec 2016), as well as investigate whether these antipsychotics were licensed to be used for the corresponding diagnoses of these patients. We also looked into whether patients were prescribed antipsychotics within BNF limits. As a part of this audit we looked into whether patients were made aware that they were on unlicensed antipsychotics or on above the BNF maximum doses of antipsychotics.

METHODOLOGY

A random sample of 50 patients was taken from the case load of the South community team as is documented on RIO. The mean age of the patients in the sample was 46.1 (SD= ±14.6) Sample selection was done by selecting every seventh patient in the patient case load (if not using antipsychotics the next patient was chosen). Patients studied involved those with F1-F19 Mental and behavioural disorders due to psychoactive substance use, F20-F29 Schizophrenia/Schizotypal/Delusional disorder, F31 Bipolar affective disorders, F32 Depression, F40-F48 Anxiety Neurotic and stress related disorders and somatoform disorders, F50-F59 Behaviour syndromes associated with physiological disturbances and physical factors, F60-F69 Disorders of adult personality and behaviour. The patients selected had to be followed up by the recovery team during the year 2016 and they had to be on an antipsychotic medication at any point during that time period. A scale was utilized to help the orderly collection of information as dose, patient diagnoses, comorbid substance use etc. SPC was relied upon for investigating the licensing of the different antipsychotics.

RESULTS

It was found that the most commonly prescribed antipsychotic was Quetiapine (28.07%) followed by Olanzapine (24.56%), Aripiprazole (14.04%) and Depot drugs (12.28%). It was found that the most commonly used depot drugs were Modecate and Depixol. It was also found that 14% of our patients were prescribed two antipsychotics at the same time. Unlicensed antipsychotics made up 17.54% of all prescribed antipsychotics. It was also found that no documentation on the system evidenced that patients were told about the use of unlicensed antipsychotics. Quetiapine and olanzapine made up 60 % of the unlicensed antipsychotics followed by risperidone and aripiprazole 40%. The conditions that were found to be given unlicensed medications were anxiety neurotic and stress related disorders and somatoform disorders (F40-48), disorders of adult personality and behaviour (F60-F69) and multiple conditions. The most common daily doses prescribed for Aripiprazole were found to be 5, 10 and 15 mg doses. For Quetiapine, it was the 300mg dose and for Olanzapine it was found to be the 10mg dose. In all but one patient antipsychotics were prescribed within BNF limits. One patient was prescribed Olanzapine 25 mg (BNF maximum dose 20 mg). Polypharmacy was found to be used more in the multiple diagnosis and schizophrenia conditions. Patients with schizophrenia and adult personality disorders were found to be the most patients who abused alcohol, cannabis and prescription opioid analgesic medications.

CONCLUSION

Antipsychotics have a range of central nervous system effects and there are situations where it becomes necessary to use them off-license. However, it is essential to explain to the patient about the unlicensed use of antipsychotics and document this on the system. The effects of unlicensed antipsychotics need to be carefully monitored and their benefits regularly assessed and recorded. Antipsychotics interact with physical health medication and could adversely affect the physical health condition. Hence it is necessary to look into healthier means of pain management and review the long term prescription of opioid analgesics. It is important to investigate more into how to manage comorbidities such as substance misuse of alcohol and cannabis and whether cross referral between services is the best way to address this issue. Further audits can look into the follow up of patients on polypharmacy, and on the general effect on disease prognosis, and physical health side effects of such regimens.

摘要

引言

社区心理健康团队为南赫里福德郡地区约400名患者提供综合服务,管理从精神分裂症到神经症及成人个性障碍等不同严重程度和复杂性的病例。抗精神病药物仍然是该团队所负责病例中患者治疗和管理的主要手段;因此,有必要详细研究此类药物的处方模式。

目的

本研究的目的是调查2016年(从2016年1月至2016年12月)南赫里福德郡社区团队中50名患者样本的抗精神病药物处方模式,以及调查这些抗精神病药物是否被许可用于这些患者的相应诊断。我们还研究了患者是否按照英国国家处方集(BNF)的限制开具抗精神病药物。作为此次审核的一部分,我们研究了患者是否知晓他们正在使用未获许可的抗精神病药物或使用的抗精神病药物剂量超过了BNF的最大剂量。

方法

从RIO记录的南社区团队的病例中随机抽取50名患者作为样本。样本中患者的平均年龄为46.1岁(标准差=±14.6)。样本选择是通过在患者病例中每隔七名患者进行选择(如果不使用抗精神病药物则选择下一名患者)。所研究的患者包括因使用精神活性物质导致的F1 - F19精神和行为障碍、F20 - F29精神分裂症/分裂型/妄想障碍、F31双相情感障碍、F32抑郁症、F40 - F48焦虑性神经症、与应激相关的障碍和躯体形式障碍患者、F50 - F59与生理紊乱和身体因素相关的行为综合征患者、F60 - F sixty nine成人个性和行为障碍患者。所选患者必须在2016年期间由康复团队进行随访,并且在该时间段内的任何时间必须正在使用抗精神病药物。使用一个量表来帮助有序收集如剂量、患者诊断、合并物质使用等信息。依靠药品特性概要(SPC)来调查不同抗精神病药物的许可情况。

结果

发现最常开具的抗精神病药物是喹硫平(28.07%),其次是奥氮平(24.56%)、阿立哌唑(14.04%)和长效注射剂(12.28%)。发现最常用 的长效注射剂是氟奋乃静癸酸酯和哌泊噻嗪棕榈酸酯。还发现14%的患者同时开具了两种抗精神病药物。未获许可的抗精神病药物占所有开具的抗精神病药物的17.54%。还发现系统中没有文件证明患者被告知使用未获许可 的抗精神病药物。喹硫平和奥氮平占未获许可抗精神病药物的60%,其次是利培酮和阿立哌唑占40%。发现被给予未获许可药物的病症是焦虑性神经症、与应激相关的障碍和躯体形式障碍(F40 - 48)、成人个性和行为障碍(F60 - F69)以及多种病症。发现阿立哌唑最常开具的每日剂量是5毫克、10毫克和15毫克。对于喹硫平,是300毫克剂量,对于奥氮平,是10毫克剂量。除一名患者外,所有患者的抗精神病药物开具均在BNF限制范围内。一名患者被开具了25毫克奥氮平(BNF最大剂量为20毫克)。发现多药联合使用在多重诊断和精神分裂症病症中使用得更多。患有精神分裂症和成人个性障碍的患者被发现是滥用酒精、大麻和处方类阿片镇痛药物最多的患者。

结论

抗精神病药物具有一系列中枢神经系统作用,在某些情况下有必要超适应证使用。然而,向患者解释抗精神病药物的未获许可使用情况并在系统中记录这一点至关重要。需要仔细监测未获许可抗精神病药物的效果,并定期评估和记录其益处。抗精神病药物与身体健康药物相互作用,可能对身体健康状况产生不利影响。因此,有必要研究更健康的疼痛管理方法并审查阿片类镇痛药物的长期处方。更深入地研究如何管理如酒精和大麻物质滥用等合并症以及服务之间的交叉转诊是否是解决此问题的最佳方式很重要。进一步的审核可以研究多药联合使用患者的随访情况,以及此类治疗方案对疾病预后和身体健康副作用的总体影响。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验